What is FreeThink Technologies?
FreeThink Technologies operates at the intersection of advanced science and pharmaceutical efficiency. The company provides a comprehensive suite of services, including stability software, analytical laboratories, and formulation development. Central to its value proposition is the ASAPprime software, a sophisticated tool designed to determine shelf life under highly accelerated conditions. By addressing complex challenges such as solubilization and controlled delivery, FreeThink enables pharmaceutical developers to navigate the regulatory landscape with greater speed and precision. Their integrated approach to packaging and formulation ensures that clients can optimize product stability while maintaining rigorous quality standards throughout the development lifecycle.
How much funding has FreeThink Technologies raised?
FreeThink Technologies has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in FreeThink Technologies
PPP
Public-Private Partnership
What's next for FreeThink Technologies?
With this late-stage capital, FreeThink Technologies is poised to accelerate its growth trajectory by enhancing its core technological offerings and expanding its laboratory capacity. The strategic focus will likely shift toward deepening the adoption of its ASAPprime platform across global markets, further cementing its status as an industry standard for stability testing. As the pharmaceutical industry continues to prioritize rapid development cycles and cost-effective formulation strategies, FreeThink is strategically aligned to capture increased market share. Future initiatives will likely involve scaling operational infrastructure to support a broader client base, ensuring that the company remains at the forefront of pharmaceutical innovation and scientific excellence.
See full FreeThink Technologies company page
